Home
Marc Voigt - Executive Director & CEO - Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.
Immutep (ASX:IMM) - Webinar Presentation
PUBLISHED
2023-06-26
Content
Marc Voigt - Executive Director & CEO - Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.
Author
| Name | Company News |